Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor
Authors:
- Yi-Yin KuYKYi-Yin Ku
- Vincent S. ChanVCVincent S. Chan
- Alan ChristesenACAlan Christesen
- Timothy GriemeTGTimothy Grieme
- Mathew MulhernMMMathew Mulhern
- Yu-Ming PuYPYu-Ming Pu
- Michael D. WendtMWMichael D. Wendt
- 7 January 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 84 (8) , 4814-4829
Abstract
The process development of a new synthetic route leading to an efficient and robust synthetic process for Venetoclax (1: the active pharmaceutical ingredient (API) in Venclexta™) is described. The redesigned synthesis features a Buchwald-Hartwig amination to construct the core ester 23c in a convergent fashion by connecting two key building blocks (4c and 26), which is then followed by a uniquely effective saponification reaction of 23c using anhydrous hydroxide generated in-situ to obtain 2. Finally, the coupling of the penultimate core acid 2 with sulfonamide 3 furnishes drug substance 1 with consistently high quality. The challenges and solutions for the key Pd-catalyzed C-N cross-coupling will also be discussed in detail. The improved synthesis overcomes many of the initial scale-up challenges and was accomplished in 46% overall yield from 3,3-dimethyldicyclohexanone 6, more than doubling the overall yield of the first generation route. The new process was successfully implemented for producing large quantities of 1 with >99% area purity.Keywords
Funding Information
- AbbVie
This publication has 47 references indexed in Scilit:
- Pioneering apoptosis-targeted cancer drug poised for FDA approvalNature Reviews Drug Discovery, 2016
- Thirty years of BCL-2: translating cell death discoveries into novel cancer therapiesNature Reviews Cancer, 2016
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyScience Translational Medicine, 2015
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapyNature Reviews Molecular Cell Biology, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Deciphering the rules of programmed cell death to improve therapy of cancer and other diseasesThe EMBO Journal, 2011
- Bcl-2–family proteins and hematologic malignancies: history and future prospectsBlood, 2008
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- The Bcl-2 family: roles in cell survival and oncogenesisOncogene, 2003
- The Hallmarks of CancerCell, 2000